Table 3.
Statistical outcomes from two-way repeated-measures ANOVAs. F values in bold-face font met statistical significance at p<0.05
| Time-Course Assessment of Single Drugs Main Effects Timepoint (row 1), Saline vs. Drug (row 2), and the Interaction (row 3) | ||||||
|---|---|---|---|---|---|---|
| Drug | Species-Typical | Passive Visual | Rest/Sleep Posture | Lip Droop | Scratch | Facial Rub |
| U50–488H 0.1 mg/kg typical KOR agonist |
F(5,25)=2.6 | F(5,25)=2.9 | F(5,25)=1.8 | F(5,25)=1.9 | F(5,25)=0.4 | F(5,25)=0.7 |
| F(1,5)=13.6 | F(1,5)=2.9 | F(1,5)=6.0 | F(1,5)=8.9 | F(1,5)=31.8 | F(1,5)=0.2 | |
| F(5,25)=4.4 | F(5,25)=3.5 | F(5,25)=1.9 | F(5,25)=2.2 | F(5,25)=2.5 | F(5,25)=1.3 | |
| Salvinorin A 0.01 mg/kg typical KOR agonist |
F(5,20)=0.8 | F(5,20)=0.7 | F(5,20)=1.3 | F(5,20)=1.9 | F(5,20)=1.2 | F(5,20)=0.4 |
| F(1,4)=3.6 | F(1,4)=7.6 | F(1,4)=2.3 | F(1,4)=2.2 | F(1,4)=27.9 | F(1,4)=5.1 | |
| F(5,20)=0.5 | F(5,20)=1.1 | F(5,20)=1.9 | F(5,20)=1.9 | F(5,20)=1.2 | F(5,20)=0.4 | |
| Nalfurafine 0.001 mg/kg atypical KOR agonist |
F(5,25)=1.3 | F(5,25)=1.4 | F(5,25)=0.8 | F(5,25)=0.6 | F(5,25)=0.9 | F(5,25)=0.7 |
| F(1,5)=7.2 | F(1,5)=4.7 | F(1,5)=7.5 | F(1,5)=8.6 | F(1,5)=45.9 | F(1,5)=1.2 | |
| F(5,25)=0.3 | F(5,25)=0.3 | F(5,25)=1.1 | F(5,25)=0.6 | F(5,25)=1.0 | F(5,25)=1.3 | |
| Triazole 1.1 0.32 mg/kg atypical KOR agonist |
F(5,25)=0.9 | F(5,25)=1.2 | F(5,25)=1.0 | F(5,25)=1.0 | F(5,25)=1.0 | F(5,25)=1.1 |
| F(1,5)=0.3 | F(1,5)=0.1 | F(1,5)=1.0 | F(1,5)=1.0 | F(1,5)=18.0 | F(1,5)=2.1 | |
| F(5,25)=0.7 | F(5,25)=1.1 | F(5,25)=1.0 | F(5,25)=1.0 | F(5,25)=1.3 | F(5,25)=0.9 | |
| Oxycodone 0.32 mg/kg mu-opioid agonist |
F(5,25)=0.2 | F(5,25)=1.2 | F(5,25)=0.7 | F(5,25)=1.4 | F(5,25)=2.2 | F(5,25)=2.3 |
| F(1,5)=5.4 | F(1,5)=2.4 | F(1,5)=0.2 | F(1,5)=3.1 | F(1,5)=6.8 | F(1,5)=7.0 | |
| F(5,25)=2.6 | F(5,25)=2.0 | F(5,25)=1.4 | F(5,25)=0.9 | F(5,25)=2.4 | F(5,25)=1.8 | |